Palisade Bio (PALI) surged to $2.96 recently, driven by strong momentum from a 125% pre-market gain and positive Phase 1 trial results for PALI-2108, which showed safety and tolerability. The stock's rally reflects optimism about its R&D progress and upcoming topline data in H1 2025. However, its valuation remains speculative, tied to future trial outcomes and funding needs.